Pure Global AI
NCT05972928Not yet recruiting

Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients

Effect of Sitagliptin on Clinical, Metabolic and Hormonal Parameters in Polycystic Ovarian Syndrome Patients
Beni-Suef UniversityPhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Polycystic Ovary Syndrome
Drug/Device/Intervention
Sitagliptin 100mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beni-Suef University
Location
Banī Suwayf, Egypt
Timeline & enrollment
Phase
Phase 2/3
Start date
Jul 30, 2023
End date
Oct 30, 2023
Enrollment
80 participants
Primary outcome

Body weight loss in Kilograms

Summary

The Study aims to determine the proposed positive influence of Sitagliptin in manipulating
 hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary
 syndrome and subsequent infertility

ICD-10 classifications
Polycystic ovarian syndromeOvarian dysfunction, unspecifiedOvarian dysfunctionOther ovarian dysfunctionNeoplasm of uncertain or unknown behaviour: Ovary
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05972928
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05972928 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Beni-Suef University and is currently Not yet recruiting. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.